Abstracts tagged "fibromyalgia"

Abstract Number: 1767 • 2016 ACR/ARHP Annual Meeting
Poor Body Image in Lupus: Is It Disease Activity, Damage, Sleep, Pain, Fatigue, Stress, Function, Medications, Depression or Fibromyalgia?
Stacy Weinberg¹, Nisarg Gandhi², Meenakshi Jolly³, Winston Sequeira² and Shilpa Arora², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³Rush, Chicago, IL
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have poorer body image (BI) than age matched controls. Few studies have been done looking at the effect…
Abstract Number: 1791 • 2016 ACR/ARHP Annual Meeting
Loss of Elbow Hyperextension in Females with Early Rheumatologic Disease Was Common in Systemic Lupus Erythematosus and Rheumatoid Arthritis but Rare in Fibromyalgia
John P. Case¹, Heidi Tucker² and Congbin Wang³, ¹Internal Medicine/Rheumatology, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ²Rush Medical College, Chicago, IL, ³Internal medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: The elbow extension angle (ELB) is commonly given as 180o although most healthy females exhibit hyperextension(1). The loss of hyperextension (LOH) in a…
Abstract Number: 2080 • 2016 ACR/ARHP Annual Meeting
Three Simple Tests to Raise the Index of Suspicion for Fibromyalgia in Primary Care
Amanda W. St. John¹, Jonathan H. Aebischer², Robert M. Bennett³, Madeleine J. Sanford², Kaitlin Z. Haws⁴ and Kim D. Jones³, ¹Anesthesiology and Pain Medicine, Oregon Health & Science University, Portland, OR, ²Department of Family Medicine, Oregon Health & Science University, Portland, OR, ³Schools of Nursing and Medicine, Oregon Health & Science University, Portland, OR, ⁴Department of Internal Medicine and Geriatrics, Oregon Health & Science University, Portland, OR
Background/Purpose: 356 patients were studied (mean age 50 ± 16.3 years, 70% female). Chart review revealed that 53 (15%) of these patients carried a…
Abstract Number: 52 • 2016 ACR/ARHP Annual Meeting
Pregabalin Dose-Response for Sleep Quality and Pain Response in Fibromyalgia: A Post-Hoc Analysis of Three Randomized Trials
Andrew Clair¹, Ed Whalen¹, Neal Thomas¹ and Lynne Pauer², ¹Pfizer, New York, NY, ²Pfizer, Groton, CT
Background/Purpose: Pregabalin is often administered for treatment of fibromyalgia (FM) at daily doses lower than approved by the US Food and Drug Administration (starting dose…
Abstract Number: 33 • 2016 ACR/ARHP Annual Meeting
Prevalence of Growth Hormone Deficiency in Fibromyalgia Patients
Thomas Romano, Private Practice, Martins Ferry, OH
Background/Purpose: Low levels of Insulin-dependent growth factor 1 (IGF-1) have been described in Fibromyalgia (FM) patients, suggesting that they have adult growth hormone (GH) deficiency.…
Abstract Number: 2200 • 2016 ACR/ARHP Annual Meeting
Association of Active Commuting and Physical Activity in Women with Fibromyalgia
Manuel Herrador-Colmenero¹, Fernando Estévez-López¹, Víctor Segura-Jiménez¹, Inmaculada C Álvarez-Gallardo¹, Alberto Soriano-Maldonado¹, Daniel Camiletti-Moirón^1,2, Virginia A Aparicio¹, Manuel Delgado-Fernández¹ and Palma Chillón¹, ¹University of Granada, Granada, Spain, ²University of Cádiz, Cádiz, Spain
Background/Purpose: Fibromyalgia symptomatology results in a low functional capacity1, limiting the daily activities and the quality of life of the patients2. Walking for commuting is…
Abstract Number: 54 • 2016 ACR/ARHP Annual Meeting
Patients with Fibromyalgia in General Have Higher Self-Report Questionnaire Scores Than Patients with Rheumatoid Arthritis: Implications for Clinical Trials and Clinical Research
Theodore Pincus¹, Isabel Castrejón¹, Joel Block² and Nathaniel Cook¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with rheumatoid arthritis (RA) who are included in clinical trials generally are selected for measures indicating high disease activity, such as more than…
Abstract Number: 42 • 2016 ACR/ARHP Annual Meeting
Small Fibre Neuropathy Biopsies (SFN) in Primary Fibromyalgia Revealed Predominant Association with Metabolic Syndrome (in addition to other known treatable causes of SFN) but No Clear Distinction Related to Biopsy Results
Euthalia Roussou¹, Johnathan Chan², Istvan Bodi³ and Aleksandar Radunivics², ¹Rheumatology, Dr, London, United Kingdom, ²Neurologist, London, United Kingdom, ³Department of Clinical Neuropathology, London, United Kingdom
Background/Purpose: To assess patients with primary fibromyalgia (pFM) for small fibre neuropathy (SFN) and to correlate biopsy results between groups and with known causes of…
Abstract Number: 2206 • 2016 ACR/ARHP Annual Meeting
Data on Treatment from Brazilian Fibromyalgia Patients Registry (EpiFibro)
José E. Martinez^1,2, Marcelo C. Rezende^1,3, Eduardo Paiva^1,4, Daniel Pollak^1,5, Milton Helfenstein Jr^1,6, Jose Roberto Provenza^1,7, Aline Ranzolin^1,8, Luiz Severiano Ribeiro^1,9, Eduardo J. R. Souza^1,10, Roberto E Heymann^1,11 and Marcos Renato Assis^1,12, ¹Brazilian Society of Rheumatology, São Paulo, Brazil, ²Rheumatology, Pontificia Universidade Católica de São Paulo, Sorocaba, Brazil, ³Santa Casa de Campo Grande, Campo Grande, Brazil, ⁴Rheumatology, Universidade Federal do Parana, Curitiba Parana, Brazil, ⁵Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil, ⁶RUA JOAO DE LACERDA SOARES, 90, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁷Rheumatology, Pontifícia Universidade Católica de Campinas, Campinas, Brazil, ⁸Hospital das Clínicas - Universidade Federal de Pernambuco, Recife, Brazil, ⁹Instituto de Previdência dos Servidores do Estado de Minas Gerais, Belo Horizonte, Brazil, ¹⁰Santa Casa de Belo Horizonte, Belo Horizonte, Brazil, ¹¹Universidade Federal de São Paulo, São Paulo, Brazil, ¹²Rheumatology, Faculdade de Medicina de Marilia, Marilia, Brazil
Background/Purpose: The Brazilian registry on fibromyalgia syndrome (EpiFibro) included 810 patients who satisfied the American College of Rheumatology Classification Criteria for Fibromyalgia (ACR1990) at the…
Abstract Number: 44 • 2016 ACR/ARHP Annual Meeting
Ambroxol for Fibromyalgia. One-Group Pretest-Posttest Open Label Clinical Observation
Laura-Aline Martinez-Martinez¹, Luis-Fernando Perez², Gumaro Acosta², Lizbeth Becerril³, Pedro Rodriguez-Henriquez⁴, Omar-Eloy Muñoz-Monroy⁵, Luis H. Silveira⁶, Angelica Vargas Guerrero⁷ and Manuel Martínez-Lavín⁷, ¹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, TX, Mexico, ²National Institute of Cardiology, Mexico, Mexico, ³Hospital Juarez, Mexico, Mexico, ⁴Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ⁵Hospital Militar, Mexico City, Mexico, ⁶Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ⁷Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico
Background/Purpose: A consistent line of investigation proposes that fibromyalgia is a sympathetically maintained neuropathic pain syndrome. Moreover it has been suggested that dorsal root ganglia…
Abstract Number: 2217 • 2016 ACR/ARHP Annual Meeting
Adherence to Drug Therapy in Patients with Fibromyalgia
Guillermo Bennasar Sr.¹, Anastasia Secco² and Marta Mamani³, ¹Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ²Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ³Hospital Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, Argentina
Background/Purpose: As in other chronic diseases, adherence to the treatment regimen of patients with fibromyalgia (FM) is low (between 30 and 80%), depending on the…
Abstract Number: 48 • 2016 ACR/ARHP Annual Meeting
Fibromyalgia Impact Is a Potential Mediator for the Associations of Self-Efficacy and Pain Catastrophizing with Physical Functioning in Persons with Fibromyalgia
Sun Yu¹, Lori Lyn Price², Jeffrey B. Driban¹, William F. Harvey¹ and Chenchen Wang¹, ¹Rheumatology, Tufts Medical Center, Boston, MA, ²Biostatistics Research Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA
Background/Purpose: Fibromyalgia (FM) is a chronic multidimensional disorder that causes physical and psychological impairment, incurring significant healthcare costs. Self-efficacy and pain catastrophizing have been shown…
Abstract Number: 2221 • 2016 ACR/ARHP Annual Meeting
Recognition of Secondary Fibromyalgia Using an Index of 3 Components of the Multi-Dimensional Health Assessment Questionnaire: 90% Agreement with ACR Criteria for Fibromyalgia
Kathryn Gibson^1,2, Isabel Castrejón³, Theodore Pincus³ and Katherine J. Bryant⁴, ¹Liverpool Hospital, Sydney, Sydney, Australia, ²Ingham Research Institute, Liverpool, Australia, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴University of New South Wales, Sydney, Australia
Background/Purpose: Secondary fibromyalgia (FM) is seen 15-20% of patients with rheumatoid arthritis (RA) (1), systemic lupus erythematosus (SLE) (2), osteoarthritis (OA), and other rheumatic diseases.…
Abstract Number: 49 • 2016 ACR/ARHP Annual Meeting
Efficacy of Mirogabalin on Patient-Reported Pain and Sleep Interference in Patients with Diabetic Neuropathic Pain: Secondary Outcomes of a Phase 2 Proof-of-Concept Study
Domenico Merante¹, Julio Rosenstock², Uma Sharma³, Karen Feins⁴, Ching Hsu⁵ and Aaron Vinik⁶, ¹Daiichi Sankyo Development Ltd, Gerrards Cross, Buckinghamshire, United Kingdom, ²Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, ³MMS Holdings Inc., Canton, MI, ⁴Daiichi Sankyo Pharma Development, Edison, NJ, ⁵Daiichi Sankyo Inc, Edison, NJ, ⁶Eastern Virginia Medical School, Norfolk, VA
Background/Purpose: Mirogabalin is a novel, preferentially selective a2d-1 ligand intended for treatment of pain associated with fibromyalgia and neuropathic pain. Mirogabalin efficacy and safety was…
Abstract Number: 2222 • 2016 ACR/ARHP Annual Meeting
Tai Chi Is More Effective Than Aerobic Exercise in Treating Fibromyalgia: A Randomized Controlled Trial
Chenchen Wang¹, Christopher Schmid², Roger A. Fielding³, William F. Harvey¹, Lori Lyn Price⁴, Jeffrey B. Driban¹, Kieran Reid³, Robert A. Kalish⁵, Ramel Rones⁶ and Timothy E. McAlindon⁷, ¹Rheumatology, Tufts Medical Center, Boston, MA, ²Brown University School of Public Health, Providence, RI, ³Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, ⁴Clinical Care Research, Tufts Medical Center, Boston, MA, ⁵Div of Rheumatology, Tufts Medical Center, Boston, MA, ⁶Center for Mind–Body Therapies, Boston, MA, ⁷Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Fibromyalgia is a complex disorder with strong psychological and pain components and is best managed with multidisciplinary therapies. Previous studies have suggested that Tai…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].